Treating the Untreatable in Rheumatoid Arthritis! Rob Armstrong, CEO, Artax Biopharma
40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.
